new and in pandemic we size our doubling and year look Seattle. a year company to have to remarkable review the the opportunity our ahead headquarters pleased of establishing despite for our was this Julie challenges the full as was you, to afternoon. progress well of significantly first our good Neoleukin as Thank as I'm and It XXXX. for our recent a priorities team Therapeutics. grew XXXX public
applications development Our lead NL-XXX, and the our novo accomplishments and the preclinical completing of for year de key protein submitting in first, program U.S. regulatory include; scientific Australia.
of tumor data another and demonstrated which after for and designing the has types, year clinical novo anticipate new as testing range the a to potent we and de monotherapy be transitioning SARS-CoV-X NL-CVXX rodents across data, to broad demonstrating Second, for activity will exciting our third, XXXX ability preclinical combination development. presenting decoy protein company prophylaxis. intranasal protect
first, de this priorities first to and novo for diligently are what year will the trial clinical we're we address protein. working with Our NL-XXX the believe fully a clinical initiate be hold
is people are we facility more year, In of February to space, work safe site. And to we our platform needs. on gradually research were protocols developing candidates the March headquarters medical to office this address on focused IND using expanded work any We've will Second, personnel It lab to third, critical and achieving to pipeline impacted occupy de novo over success Seattle. long-term and to and new ambitious by year in home unmet from able as culture this a workforce keep in COVID-XX and research our continue been work-related last future invest portion protein other our bring we to guidelines our back of to work we without We goals. infections. We've our intended safety our first enabling a and pandemic. believe since able the greatly healthy. staff instituted has were been we
testing Drug dose to novo received cells to January in requesting the potent precision and or In roll is procedures CDXX forms administration new with alpha methods actually Australia. a development native November, a potential or that X, investigational binding with XXXX, are cells we Administration. the remained of XXXX Washington protein refine from drug cells. deliver assay we NK of In the that which we T approaches clinical towards from designed U.S. program, of IL-X December on and XXXX the Throughout develop IL-X trial advancing testing. NL-XXX IL-XX, clinical and we the a native preparation no NL-XXX hold lead IL-X. receptors and completely immunotherapy submitted we CTN IL-XX both and policies submitted On potency and and monitor notification dose on cells proceeds, or both the State As is an de expand for of demonstrate cancer-fighting the increased guidance of appropriate. intended we letter Unlike other out NL-XXX. IND affected FDA NL-XXX to for application of NK new and NL-XXX T and new modified compared continue a increase subunit a in focused application as or will Food will as use agonist vaccines our our to clinical CDC, the
first are as the to patients hold, resolve half begin XXXX. to and the We address to working questions clinical as well the FDA's enrollment of quickly expect of currently possible as in as
is the hold provide lifted. notification will clinical We when
enroll in safety, dosing including patients pharmacokinetics, cell a renal in of indication carcinoma The schedules solid first or specific focus intravenous to pharmacodynamics trial Our After include will immunogenicity, evaluation assess melanoma. tumors. order the with and recommended activity. human schedule to monotherapy up levels NL-XXX will and is in relapsed NL-XXX patients administration clinical we on plan with trial refractory expansion identified, of antitumor dose and XXX multiple to of cohorts
administration In NL-XXX to to of microenvironment the decrease concentrations tumor addition exposure. to systemic XXXX. achieve the to trial, drug the potential begin evaluating to begin we the end higher a company in local systemic risks order and expects in of our local administration by trial planning of study The are
and presented NL-XXX checkpoint Society multiple across to many our data inhibitors NL-XXX and tumor of could with regimens. agents. care that that combined and or in Cancer for demonstrated in variety combination These novel models. a NL-XXX combination preclinical broadly with and evaluation in syngeneic NL-XXX models antitumor variety tumor wide we Annual when at of on has synergistic targeting expand work additive and immunotherapies activity experiments with of its of of of indications knowledge a Meeting. the antibodies Immunotherapy We believe standard November continue NL-XXX highlighted data activity through In XXXX of We the preclinical
Turning to technology beginning de explore platform to possibilities pipeline, now the are offered. of our range Neoleukin has novo the that protein just we
Our exactly of structural approach the affinity, de tackle size shift novo and in completely molecules serious optimize the biological revolutionary both represents specific a algorithms including can are parameters, to treat engaged. speed way By target The we drugs sites is our computational potency, designed proteins COVID-XX, prevent applicability stability, high-resolution multiple new new and creating build of to using design problems. using of developed binding to demonstrates NL-CVXX, receptor or part development protein de novo the which broad information.
our receptor past shown when this blocking ACEX has binding reported of been as prevent multiple published to As Science cell and association optimized decoy protein with the SARS-CoV-X spike intranasally. administered the NL-CVXX cellular of and preventing an entry. affinity, in acts high from viral protein ACEX human serious vitro November, SARS-CoV-X protect in consequences to lines infection infection to hamsters with and
team novo of highlighting able three months, in platform. de protein under Our this molecule to our the speed was develop
and resiliency planning We of against this variants of are evaluating molecule trial. the SARS-CoV-X human first for in currently a potential new
capabilities and remain as the our the on in to to continue pipeline design. expanding landscape We're the sophistication protein like de to computational I'd and focused evolves. will ongoing SARS-CoV-X activities. discuss methods novo now evaluate of We research leaders program our
stability Our include; conditional to to us research inflammatory the would will activation. approach suppressing or choosing high targets novo that impact and with receptors impact enable or priorities the de immune activating specificity, increase help benefit first, a the cells for of Understanding greatest biology to patients have specific diseases. cancer from target
of immunogenicity. us distribution developing the modifying therapies split presenting emerging one featured in conditional activation data of efforts will that of novo are candidates this hyperstable, programs the we can potent remain XXXX; Second, research year. of novo more behaved on half de so continue de and focus protein proteins, of that at in designs. or bio minimize third, the to vivo that therapeutic These well AACR second widening enable anticipate technology leaders We and on during as strategies, the risk of the our field the our to and index increasing therapeutic in was immuno-oncology by such understanding
by these ambitious are and of and accomplishments goals possible dedicated talented our employees. made All
had Our we full-time team this growth of clinical. has grown The significantly of majority end approximately in the XXXX XX past At year. research in the and employees. occurred
are of to our the company's call Board Counsel. And and Holly Foundation, and legal is experience discuss Counsel Martin General in the an to advance Directors. that, Bob? expect to to CEO Gates like of & the platform our Vance, candidates mediated a Associate therapeutic of former Melinda We XXXX. corporate and continue Bob, at year-end turn General for immune In of to Neoleukin team the helped as XXXX. experienced the to of of a matters. part Principia transactional few diversity, wealth now at joined financials. I'd like Martin assembled brings diseases. latter where additions appointment September, committed Bill Babler in served We've I'd dedicated and highlight President inclusion. October, announced an environment fostering and of specific equity, as he previously to With over XXXX during our we Biopharma, team Holly grow to during
